Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs
Marcinak, J F, Viswanathan, P, Arora, V, Roebel, L E, Strack, T R, Leifke, EVolume:
91
Language:
english
Journal:
Clinical Pharmacology & Therapeutics
DOI:
10.1038/clpt.2011.257
Date:
March, 2012
File:
PDF, 293 KB
english, 2012